Possible post-COVID epilepsy: A review of epilepsy monitoring unit admissions during the two years of COVID-19 pandemic

Dunn, Eric; Ibrahim, Fatimah; Neme-Mercante, Silvia; Nair, Dileep; Morris, Spencer; Wang, Irène; Punia, Vineet

doi:10.1016/j.ebr.2023.100584

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, studies have identified that COVID-19 can cause a temporary loss of smell and strokes related to blood clotting and inflammation in brain blood vessels (Goldenberg et al, 2022). New-onset epilepsy noted in 0.3% of patients within 6 months of COVID-19 infection, and three cases of post-COVID-19 epilepsy were identified after nonsymptomatic to mild disease (Dunn et al, 2023). COVID-19 infection affects the nervous system, including epilepsy patients, Sorokina et al, 2023 mention the symptoms of autonomic nervous system dysfunction and psychological disorders such as depression and anxiety.…”

Section: Introductionmentioning

confidence: 99%

Unraveling the Shared Genetic Elements Among COVID-19 and Epilepsy: A Computational and Bioinformatics Analysis

Nagendran,

Murugesan,

Natarajan

2024

MEDIN

View full text Add to dashboard Cite

The outbreak of COVID-19 linked to the SARS-CoV-2 virus has raised worries about its potential to worsen pre-existing health issues such as autoimmune conditions. One common autoimmune condition seen across all individuals is epilepsy. Our detailed computational study examined the complex connection between COVID-19 and epilepsy, with a focus on their possible impact on neurodegenerative disorders. Leveraging transcriptome analysis, we aimed to interpret shared pathways and molecular biomarkers between COVID-19 and epilepsy using RNA-seq datasets. Cutting-edge bioinformatics tools facilitated Network, Enrichment, and route analysis, along with the identification of pivotal gene signatures, notably through comprehensive exploration of machine learning methods and protein-protein interactions. This work identified 1040 common differentially expressed genes (DEGs), forming the basis for unraveling shared pathways and potential drug targets. By employing statistical methods and diverse network analyses, we meticulously identified genetic elements shared between COVID-19 and epilepsy. The analysis reveals that 10 key genes, including CATIP, CDC25C, GPR132, NTS, PDE8B, PLK1, SLC12A9, SPC25, TUBAIA, and TYMS, are crucial in bridging transcriptomic alterations across various scenarios. A subset of these genes exhibited existence within distinct regulatory networks, signifying their significant role in the shared disease mechanisms of COVID-19 and epilepsy. Notably, CDC25C, PLK1, and TYMS emerged as prominent genes within the COVID-19 and epilepsy networks, strongly suggesting their vital roles in connecting regulatory mechanisms across these conditions. Further validation through molecular docking studies will confirm the significance of CDC25C, PLK1, and TYMS, potentially shedding light on new opportunities for targeted therapeutic interventions aimed at reducing the risk of seizures in individuals affected by COVID-19 and epilepsy.

show abstract

Section: Introductionmentioning

confidence: 99%